Skip to main content
Year archive

Karolinska Development — 2020 filings

All 40 regulatory filings released by Karolinska Development (KDEV) in 2020, sourced directly from the official regulator.

40 Filings
2020 Period
2020 filings (40)
Filing Released Lang
Karolinska Development ökar det bokförda värdet av innehavet i Umecrine Cognition med SEK 234 miljoner
Net Asset Value
2020-12-29 Swedish
Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
Earnings Release Q4 2020
2020-12-29 English
Karolinska Development's portfolio company Aprea Therapeutics reports results from Phase 3 study of eprenetapopt in MDS
Legal Proceedings Report
2020-12-28 English
Karolinska Developments portföljbolag Aprea Therapeutics rapporterar resultat från fas 3-studie av eprenetapopt i MDS
Legal Proceedings Report
2020-12-28 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-11 Swedish
Regulatory Filings 2020
Regulatory Filings
2020-11-11 English
Karolinska Developments resultat för tredje kvartalet 2020 påverkas negativt till följd av aktiekursutvecklingen i portföljbolaget Aprea Therapeutics
Earnings Release Q3 2020
2020-09-30 Swedish
Karolinska Development's earnings for the third quarter 2020 negatively affected by the share price development in its portfolio company Aprea Therapeutics
Earnings Release Q3 2020
2020-09-30 English
Karolinska Developments finansdirektör lämnar bolaget
Board/Management Information
2020-09-08 Swedish
Karolinska Development's CFO is leaving the company
Board/Management Information
2020-09-08 English
Karolinska Developments styrelseledamot Magnus Persson lämnar sitt uppdrag
Board/Management Information
2020-08-25 Swedish
Karolinska Development’s Board director Magnus Persson resigns from his position
Board/Management Information
2020-08-25 English
Karolinska Development’s Chairman of the Board resigns from his position
Board/Management Information
2020-08-20 English
Karolinska Developments styrelseordförande lämnar sitt uppdrag
Board/Management Information
2020-08-20 Swedish
Karolinska Development säljer del av innehavet i portföljbolaget Aprea Therapeutics och erhåller netto 39 miljoner SEK
Major Shareholding Notification
2020-07-08 Swedish
Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 39 million
Share Issue/Capital Change
2020-07-08 English
Karolinska Development’s Annual General Meeting 2020
AGM Information
2020-06-15 English
Karolinska Developments årsstämma 2020
AGM Information
2020-06-15 Swedish
Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva kompletterande resultat från en fas 2a-studie av golexanolon
Earnings Release FY 2020
2020-05-08 Swedish
Karolinska Development’s portfolio company Umecrine Cognition presents positive additional results from a phase 2a study of golexanolone
Regulatory Filings
2020-05-08 English
Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
AGM Information
2020-05-07 Swedish
Notice of Annual General Meeting in Karolinska Development AB (publ)
AGM Information
2020-05-07 English
Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 59 million
Report Publication Announcement
2020-04-13 English
Karolinska Development säljer delar av innehavet i portföljbolaget Aprea Therapeutics och erhåller netto 59 miljoner SEK
Earnings Release FY 2020
2020-04-13 Swedish
Karolinska Developments portföljbolag Umecrine Cognition rapporterar fas 2a-data för läkemedelskandidaten golexanolon
Regulatory Filings
2020-04-03 Swedish
Karolinska Development’s portfolio company Umecrine Cognition announces results from a phase 2a clinical study of golexanolone
Legal Proceedings Report
2020-04-03 English
Karolinska Development investerar i vaccinprojekt mot allvarliga virussjukdomar
Capital/Financing Update
2020-03-27 Swedish
Karolinska Development invests in vaccine project to combat serious viral diseases
Capital/Financing Update
2020-03-27 English
Annual Report 2019
Annual Report FY 2019
2020-03-26 Swedish
Annual Report 2019
Annual Report FY 2019
2020-03-26 English
Karolinska Development changes date for the Annual General Meeting
Report Publication Announcement
2020-03-16 English
Karolinska Development meddelar nytt datum för årsstämma
Regulatory Filings
2020-03-16 Swedish
Karolinska Development appoints Johan Dighed as General Counsel
Board/Management Information
2020-03-09 English
Karolinska Development utser Johan Dighed til Chefsjurist
Board/Management Information
2020-03-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-13 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-13 English
Karolinska Developments portföljbolag Aprea Therapeutics erhåller FDA Breakthrough Therapy Designation
Regulatory Filings
2020-01-30 Swedish
Karolinska Development's portfolio company Aprea Therapeutics receives FDA Breakthrough Therapy Designation
Regulatory Filings
2020-01-30 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-01-02 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-01-02 Swedish